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Abstract
Background: Early detection and treatment of neuropathy in leprosy is important to prevent disabilities. A recent
study showed that the Nerve Conduction Studies (NCS) and Warm Detection Thresholds (WDT) tests can detect
leprosy neuropathy the earliest. These two tests are not practical under field conditions, however, because they
require climate-controlled rooms and highly trained staff and are expensive. We assessed the usefulness of alternative
test methods and their sensitivity and specificity to detect neuropathy at an early stage.
Methods: Through a literature search we identified five alternative devices that appeared user-friendly, more affordable,
portable and/or battery-operated: the Neuropad®, Vibratip™, NC-Stat®DPNCheck™, NeuroQuick and the Thermal Sensibility
Tester (TST), assessing respectively sweat function, vibration sensation, nerve conduction, cold sensation and
warm sensation. In leprosy patients in Bangladesh, the posterior tibial and sural nerves that tested normal for
the monofilament test and voluntary muscle test were assessed with the NCS and WDT as reference standard tests.
The alternative devices were then tested on 94 nerves with abnormal WDT and/or NCS results and on 94 unaffected
nerves. Sensitivity and specificity were the main outcomes.
Results: The NeuroQuick and the TST showed very good sensitivity and specificity. On the sural nerve, the NeuroQuick
had both a sensitivity and a specificity of 86%. The TST had a sensitivity of 83% and a specificity of 82%. Both the
NC-Stat®DPNCheck™ and Vibratip™ had a high specificity (88% and 100%), but a low sensitivity (16% and 0%). On
the posterior tibial nerve, the NeuroQuick and the TST also showed good sensitivity, but the sensitivity was lower
than for the sural nerve. The Neuropad® had a sensitivity of 56% and a specificity of 61%.
Conclusions: The NeuroQuick and TST are good candidates for further field-testing for reliability and reproducibility.
The feasibility of production on a larger scale should be examined.
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Background
Leprosy is a major cause of peripheral neuropathy in low
resource countries, affecting sensory, motor and autonomic
nerve functions. Complications of neuropathy are sensory
loss and muscle weakness. Earlier studies found that 10% to
55% of newly diagnosed patients already showed one or
both of these clinical symptoms [1–4], and that add-
itionally, up to one fourth developed neuropathy during
or after treatment [5]. Disabilities may develop if neur-
opathy remains untreated or is treated too late. Worldwide
over three million people are living with disabilities due to
leprosy [6]. Timely detection and treatment of neuropathy
is essential to prevent disabilities.
Sensory nerve function impairment (NFI) is often the first
symptom of leprosy neuropathy. Sensory NFI is typically
detected with monofilament tests (MFT) or ballpoint tests,
and motor function is assessed with voluntary muscle tests
(VMT). It is assumed that when sensory impairment is
clinically detectable, quite some damage has already been
done to the nerves, the so-called subclinical neuropathy [7].
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Methods to detect neuropathy in such early stages were
studied in the INFIR (ILEP Nerve Function Impairment
and Reactions) study [4]. To find the most sensitive
methods, changes in the nerves of leprosy patients were
monitored over time with multiple methods assessing
different modalities of neuropathy. Nerve conduction
studies (NCS) were found to be affected most frequently,
followed by warm detection thresholds (WDT). These two
methods were able to detect abnormalities in the nerves up
to twelve weeks before MFT became abnormal. The NCS
method assesses the large Aβ-fibres, responsible for percep-
tion of vibration, touch and pressure. The WDT method
tests the small myelinated Aδ- and unmyelinated C-fibres,
which mediate pain, warm- and cold sensation and govern
the autonomic functions – e.g. sweating [8–11].
Even though NCS and WDT are highly valuable to
detect early neuropathy, these devices are not optimal
for field use in leprosy endemic areas. They are costly,
require well-trained staff and need stable environmental
(temperature) conditions and stable electricity supply.
There is a need for cheap, easy-to-use, sensitive and re-
liable screening tools to detect early neuropathy. Our
aim was to find potential alternative tests methods that
can detect early neuropathy in leprosy patients and to
compare the sensitivity and specificity of these methods
when assessed in field conditions, using NCS or WDT
as reference standard test.
Methods
A literature search was conducted to identify user-friendly,
portable devices used for the diagnosis of early neuropathy,
regardless of the pathology. We covered the Embase,
Medline and Cochrane databases and the search engine
Google, using search terms related to ‘neuropathy’, ‘diagnosis’,
‘device’ and ‘simple’ (see Additional file 2).
The search resulted in 18 possibly eligible devices
(Table 1). This selection was narrowed down based on
the following requirements: costs less than €1500; avail-
ability; easiness of use – i.e. no extensive training required;
and practicality and suitability for field conditions: small
portable, battery-operated device providing direct results
without the need for additional (computer) analyses. We
also sought to cover different modalities of neuropathy.
Selected alternative devices
The final selection consisted of the Neuropad® (TrigoCare
International), Vibratip™ (McCallan Medical Limited),
NC-Stat ®DPNCheck™ (NeuroMetrix, Inc.), NeuroQuick
(Schweers) and the Thermal Sensibility Tester (TST)
(World Health Organization). These are depicted in Fig. 1.
For this study, the devices were kindly donated or lent to
us by the producers. The TST was borrowed from the
Netherlands Leprosy Relief organization.
The Neuropad is a patch designed to test the autonomic
function of the diabetic foot by assessing sweat production.
The colour of the patch changes from blue to pink due to a
chemical reaction between the complex salt anhydrous
cobalt-II-chloride and sweat on the skin. The main out-
come is whether the patch turned completely pink after ten
minutes, and the total time to complete colour change is
recorded as well. The Neuropad is applied on the great toe
or on the plantar surface of the foot between the first and
second metatarsal head. The Vibratip is a pocket-sized de-
vice to test vibration sensation. This disposable, battery-
operated device produces a stimulus of 128 Hz, comparable
with a tuning fork, and is activated by pinching. The main
outcome is whether vibration is felt.
The automated NC-Stat DPNCheck evaluates sensory
nerve conduction of the sural nerve. Offering an alternative
to standard NCS, this device is hand-held, battery-operated,
fast and user-friendly, as general health care providers can
handle it with minimal training. The sural nerve is stimu-
lated with a 100 mA current, and the signal is detected
orthodromically by a biosensor at 92.2 mm from the simu-
lation probes. Conduction velocity and amplitude are the
main outcomes.
The portable NeuroQuick device tests cold sensation
with an airflow produced by the integrated adjustable
fan. The fan speed is increased until the patient perceives
the airflow. The outcome, fan speed on a 0 – 9 scale, is
compared with a normal threshold to define whether the
sensory nerve function is impaired.
The pen-sized Thermal Sensibility Tester (TST) assesses
warm sensation. It was originally designed to test sensation
in leprosy skin lesions [12]. Both ends of the pen have a little
metal disc, one of which adjusts to room temperature and
one becomes warm when switched on, with a temperature
between 45 °C and 60 °C depending on environmental
temperature [13]. The main outcome is whether the patient
can distinguish the warm disc.
Patients and controls
The subjects were all leprosy patients, diagnosed by en-
larged peripheral nerves, skin lesions and/or a positive
skin smear test. Patients who had normal MFT and
VMT results for the posterior tibial and sural nerves
were included when they had abnormalities in at least
one sural or posterior tibial nerve with NCS and/or
WDT test. Patients were excluded from the study when
they suffered from other diseases that may affect the
nerve function, e.g. diabetes. Patients under the age of
18 or over 70 years were excluded as well. Patients on
prednisolone treatment were excluded from Neuropad
testing, as a rare side effect of this drug is hyperhidrosis.
To assess the specificity of the devices we also needed to
test nerves with normal NCS and/or WDT. When one
of the body sides of the included patients had normal
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Fig. 1 Pictures of the five devices. a Vibratip, b NeuroQuick, c Neuropad, d NC-stat DPNCheck, e Thermal Sensation Tester
Table 1 Results literature search and reasons for final selection
Included tests Modality Reason selected
NeuroQuick Cold sensation Portable, battery-operated
Neuropad Sweat function Easy, direct results, no training
NC-Stat DPNCheck Nerve conduction Portable, battery-operated
Vibratip Vibration Portable, battery-operated
Thermal Sensibility Tester Warm sensation Portable, battery-operated
Excluded tests Modality Reason not selected
NerveCheck Warm, cold, pain and vibration sensation Portable, battery operated, not available at the moment
of this study
Tiptherm Cold sensation Weakest performance compared with other tests [19]
Neurometer Nerve conduction Expensive
Biothesiometer Vibration Expensive
Neurotip Touch sensation Low expected sensitivity, comparable to MFT
Neuropen Pain sensation Pain sensation loss is at a later stage than touch sensation
loss [16, 40]
Sudoscan Sweat function Expensive
EzScan Sweat function Expensive
Bumps Touch sensation Low sensitivity, comparable to MFT
LDI-flare Axon reflex–induced flare after heating
skin (Doppler Imager)
Not portable, power needed
NervePace Nerve conduction Assesses motor latencies, while sensory conduction is
more often affected in leprosy neuropathy
Neurosentinel Nerve conduction Similar to DPNCheck, only assessed Median nerve, which
is less often affected in leprosy neuropathy
Thermotropic liquid
Chrystal strip assessment
Skin temperature Works when only one body side is affected (needs to be
compared with normal side)
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nerve conduction and/or WDT test results for the sural
or posterior tibial nerve, this nerve was taken as control.
To achieve the calculated number of normal nerves we
also had to include a number of leprosy patients with only
normal NCS and/or WDT results as control subjects.
Test procedure
The study took place in the Danish Bangladesh Leprosy
Mission hospital at the Rural Health Program (RHP) de-
partment in Nilphamari, which is run by The Leprosy
Mission International Bangladesh. Leprosy affected per-
sons with normal VMT and MFT results for sural and
posterior tibial nerves were sent to Nilphamari RHP
from the nearby field clinics. There, they were again
assessed again with these tests, according to a previous
described protocol [14]. In short, sensory function was
assessed on three test-sites for each nerve with a stand-
ard set of Semmes-Weinstein monofilaments, of which
the 2 g filament represented the normal threshold for
the foot. Motor function was assessed with the 0 – 5
Medical Research Council scale [15]. An MFT score
under 3 and a VMT score of 5 were considered normal,
as these are the thresholds used in large, recent leprosy
studies [4, 16].
Reference standard tests
When MFT and VMT results were normal, the reference
standard tests (sensory NCS and WDT tests) were car-
ried out. Sensory NCS tests were performed for the sural
nerve only, as we considered this method unreliable for
the posterior tibial nerve. Sural NCS were recorded anti-
dromically at 14 cm from the standard stimulation site.
The test was done with the Neurocare 2000 W EMG
machine (BioTech Ltd., Mumbai), and a nerve was con-
sidered affected when either amplitude or velocity was
impaired. The WDT test was carried out using TSA II
(MEDOC, Israel) for both sural and posterior tibial
nerves, on respectively the mid-lateral border of the foot
and the plantar aspect of the great toe. Both reference
standard tests were done bilaterally, in an air-conditioned
room by two experienced assessors who showed good
inter-tester reliability (intraclass correlation coefficient of
sural SNC, Velocity: 0.89; Amplitude: 0.99). The outcomes
were compared with age-adjusted normal values previ-
ously established for the TENLEP trial at Nilphamari
Rural Health Program (using the 97.5th percentile) [14].
However, for the posterior tibial nerve, WDT cut-off levels
were set at the maximum temperature reached with the
TSA, i.e. 50 °C. Applying this cut-off, none of the patients
had abnormal values. Therefore, we redefined the thresh-
old for abnormality by using the 95th percentile from the
normative studies in the TENLEP trial, instead of the
originally used 97.5th percentile.
Alternative devices
All five tests but one were performed for the sural nerve,
which is the most commonly affected nerve in leprosy
[17, 18]. The one exception was the Neuropad test,
which was carried out on the posterior tibial nerve, since
this test has been validated for the sole of the foot only.
We tested the other two small nerve fibre tests – the
NeuroQuick and the TST – on the posterior tibial nerve
as well (Table 2). Not all patients were tested with all de-
vices, for two reasons. First, only the nerve(s) identified as
abnormal by one of the reference standard tests and their
contralateral normal side were assessed with the alternative
devices. Second, only the alternative devices that assessed
the same type of nerve fibre – small (WDT) or large
(NCS) – as the abnormal reference standard test were
applied (see Table 2). For example, in a patient with abnor-
mal sensory NCS result for one sural nerve we tested both
sural nerves with NC-Stat DPNCheck and Vibratip (large
fibre). The tests with the alternative devices were carried
out on the same day as the reference standard tests, by one
trained assessor (MR) who was blinded to the NCS and
WDT results. The tests were done in the open air, without
fan or air-conditioning to mimic field circumstances, in a
random order following a randomization table created in
Excel. Before testing, the assessor thoroughly explained and
demonstrated the test procedures to the patient.
The Vibratip, NeuroQuick and TST assessed the sural
nerve at the mid-lateral border of the foot. With the
Vibratip, the skin was touched twice for approximately
one second, and randomly once with vibration and once
without vibration. After the second touch, the patient
was asked during which of the two touches vibration
was felt. The test was repeated two more times. The
patient’s vibration sensation was recorded as normal if
the response was correct at least twice [19]. The outcome
of the Vibratip tests was compared with the outcome of
the NCS. A similar procedure was followed for the TST:
the patient’s skin was touched twice for about three sec-
onds, randomly once with the warmed disc and once with
the ambient temperature disc. After the second touch, the
patient was asked which of the two touches was perceived
as warm. The test was repeated two more times. When
the answer was correct at least twice, the patient’s warmth
sensation was recorded as normal. The outcome of the
TST was compared with the outcome of the WDT. The
NeuroQuick test was started at fan speed level 0 and the
device was then held for five seconds at a distance of
23 cm from the foot. This exact distance is shown by two
crossing laser beams. When the patient did not perceive
the airflow, the fan speed was increased by one level and
held above the foot for another five seconds. This process
was repeated until the airflow was perceived. The total
procedure was repeated two more times and the mean of
three measurements served as the outcome of the test.
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This outcome was classified as either normal or abnormal
based on the cut-off levels of the normative test. The ref-
erence test used for comparison was WDT.
For the test with the NC-Stat DPNCheck, the standing
patient placed the lower leg on a chair such that the
muscles were relaxed [20]. The skin was cleaned with
alcohol, a biosensor was inserted in the device and gel
was applied on the stimulating probes. The sural nerves
were stimulated for 10 – 15 s, just posterior to the lateral
malleolus. Both velocity and amplitude, automatically
corrected for skin temperature, were read directly from
the device. The manufacturer suggests four severity cat-
egories: normal (velocity > 40 m/s and amplitude >4 μV),
mild (velocity < 40 m/s, but amplitude >4 μV), moderate
(amplitude 1 – 4 μV), and severe (amplitude <1 μV). The
outcome of the DPNCheck was compared with the out-
comes of the NCS. The Neuropad, NeuroQuick and TST
were applied on the plantar side of the great toe. Similar
procedures as described above were followed for Neuro-
Quick and TST. The Neuropad was applied after the
patient had acclimatised for ten minutes with bare feet.
For each Neuropad test, the total time to complete colour
change from blue to pink was recorded as outcome, or if
the change was not complete, the colour of the patch after
ten minutes was noted (blue/pink or blue). The outcome
of the Neuropad test was compared with the outcomes of
the WDT. After all the tests had been finished, we asked
the patient which of the five tests he or she valued the best
and the worst and why. We also asked the assessor’s opin-
ion on the practicality of the tests and we looked at the
costs.
Ethics
This is a sub-study of the TENLEP trial, for which ethical
approval was given by the Bangladesh Medical Research
Council (BMRC/NREC/2010-2013/533). An informed writ-
ten consent was obtained from all participants.
Analyses
Sample size calculations for an expected sensitivity of
0.60 and a confidence interval width of 0.20 resulted in
92 nerves per test. A similar number of normal nerves
should be tested to determine the specificity at 0.60.
A normative study was carried out for the NeuroQuick
to define the cut-off for abnormality. We tested the pos-
terior tibial and sural nerves of 50 healthy males and 50
healthy females between 18 and 60 years of age. The
NeuroQuick test procedure was as described above. As
the outcomes for left and right body side did not differ
significantly, the average of both body sides was used to
calculate the normal thresholds. The correlation of
NeuroQuick outcome with sex and age was tested with
Spearman’s rho. Only age was significantly related with
the NeuroQuick outcome for both nerves (sural: r = 0.64,
P < 0.001; posterior tibial: r = 0.57, P < 0.001). We there-
fore used a regression equation to calculate an age-related
cut-off for abnormality. For the sural nerve, the Neuro-
Quick result was considered abnormal when larger than
0.02 × Age + 3.4, and for the posterior tibial nerve when
larger than 0.01 × Age + 3.3.
As primary outcome for our study, the sensitivity and
specificity of each alternative device were calculated
against the appropriate reference standard test – NCS or
WDT– with their 95% confidence intervals. In addition,
the positive and negative likelihood ratios and area under
the curve (AUC) were calculated for each alternative de-
vice. A P-value <0.05 was considered to be statistically
significant.
Results
We enrolled 209 patients, and examined a total of 95
abnormal and 89 normal sural nerves with NCS, 94 ab-
normal and 90 normal sural nerves with WDT, and 75
abnormal and 115 normal posterior tibial nerves with
WDT. The majority of patients had paucibacillary leprosy
(67%) and were still on anti-leprosy multi-drug treatment
(55%). On average leprosy had been diagnosed 11 months
earlier. One patient was excluded because he was diag-
nosed with diabetes. The patients’ demographic and clin-
ical characteristics are presented in Table 3.
All patients tested with the Vibratip were able to detect
the vibration for all three touches, irrespective of whether it
was tested on an abnormal or normal nerve. TST and Neu-
roQuick outcomes are given in Table 4. Abnormal nerve
conduction was indicated by the NC-Stat DPNCheck in
14% of the sural nerves. One nerve was mildly affected, 18
moderately affected and seven severely affected. The colour
Table 2 Modality, nerve type and reference standard test for the alternative devices
Test Modality Nerve Nerve fibre type Reference standard test
NC-Stat DPNCheck Conduction Sural Large fibre (Aβ) NCS sural
Vibratip Vibration Sural Large fibre (Aβ) NCS sural
NeuroQuick Cold sensation Sural and posterior tibial Small fibre (Aδ) WDT sural/ PT
TST Warm sensation Sural and posterior tibial Small fibre (C) WDT sural/ PT
Neuropad Sweat function Posterior tibial Small fibre (C) WDT PT
PT posterior tibial nerve
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of the Neuropad had changed completely after ten minutes
in 90 cases, and in 77 cases some blue was still visible.
None of the pads remained completely blue. Mean time
until complete colour change was 7.5 (range 2 to 10) mi-
nutes. Excluding the cases without complete colour change,
the mean time was 4.9 min.
The sensitivity, specificity, positive and negative likeli-
hood ratios of all alternative devices are shown in Table 4.
For the sural nerve, the NeuroQuick had the highest
sensitivity and specificity (both 86%), closely followed by
the TST (respectively 83% and 82%). The two devices
assessing large fibre neuropathy in the sural nerves, the
Vibratip and NC-Stat DPNCheck, had poorer outcomes.
The sensitivity of the Vibratip was 0%; the specificity
100%. For the posterior tibial nerve, the NeuroQuick
showed the highest sensitivity as well (93%), but its specifi-
city was lower than that of the TST. The sensitivity and
specificity of the Neuropad were average (56% and 60%).
The highest positive likely hood ratio was that of the
NeuroQuick for the sural nerve: 6.0 (3.6 – 10.0).
Patients’ and assessor’s preferences
Sixty-eight patients were tested with at least four out of
the five tests. More than half (53%) preferred the TST,
mainly because they found it easy to feel a difference in
warmth. The second favourite test was the Neuropad
(25%), also because it was easy as it does not require any re-
sponse from the patient. The Vibratip and the NeuroQuick
were preferred by respectively 13% and 9%. When asked
which test was least preferred, 54% answered the NC-Stat
DPNCheck. The main reason was that it was too painful.
The second least preferred test was the NeuroQuick (24%),
since it was too difficult and third the Neuropad (22%),
because it was seen as time consuming.
The assessor (MR) indicated he preferred the TST and
Neuropad for their ease of use. He pointed out that for
Table 3 General characteristics of the patients (n = 209)
Characteristics SD
Sex (% male) 57%
Age (mean, years) 35.3 11.2
Height (mean, cm) 157 8
Weight (mean, kg) 51 9
Time since diagnosis (mean, months) 11 9
RFT (%) 46%






WHO classification (% PB) 67%
SD standard deviation, RFT Released from anti-leprosy treatment, RJ Ridley-Jopling,
WHO World Health Organisation
Table 4 Outcomes of the index tests and reference standard test, sensitivity and specificity (95% CI)
Reference standard test
Alternative devices Abnormal Normal Sensitivity Specificity AUC Positive Likelihood ratio Negative Likelihood ratio
Sural NCS (n) 95 89
NC-Stat Abnormal 15 11 16% 88% 0.52 1.3 1.0
DPNCheck Normal 80 78 (9 – 25) (79 – 94) (0.43 – 0.60) (0.6 – 2.6) (0.9 – 1.1)
Vibratip Abnormal 0 0 0% 100% 0.50 1.0
Normal 95 89 (0 – 4) (96 – 100) (0.41 – 0.58) – (1.0 – 1.0)
Sural WDT (n) 94 90
TST Abnormal 78 16 83% 82% 0.83 4.7 0.2
Normal 16 74 (74 – 90) (73 – 89) (0.76 – 0.89) (3.0 – 7.4) (0.1 – 0.3)
NeuroQuick Abnormal 81 13 86% 86% 0.86 6.0 0.2
Normal 13 77 (78 – 92) (77 – 92) (0.80 – 0.92) (3.6 – 10.0) (0.1 – 0.3)
Posterior tibial WDT (n) 75 115
Neuropad Abnormal 42 35 56% 61% 0.59 1.5 0.7
Normal 33 57 (44 – 67) (51 – 72) (0.51 – 0.67) (1.1 – 2.1) (0.5 – 1.0)
Missing 23
TST Abnormal 60 50 83% 57% 0.70 1.9 0.3
Normal 12 65 (72 – 91) (47 – 66) (0.63 – 0.76) (1.5 – 2.4) (0.2 – 0.5)
NeuroQuick Abnormal 67 68 93% 41% 0.67 1.6 0.2
Normal 5 47 (85 – 98) (32 – 50) (0.60 – 0.74) (1.3 – 1.9) (0.1 – 0.4)
AUC area under the curve, NCS Nerve Conduction Studies, TST Thermal Sensibility Tester, WDT Warm Detection Thresholds
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the patient the TST and the Vibratip are the best, since
the warmth and vibration are easily detected. The assessor
furthermore reported that the TST and Vibratip are the
fastest tests.
Costs
We have not performed a cost-effectiveness analysis,
though still would like to present the costs of the de-
vices. The retail price for Neuropads for clinics is $11
per test, containing two pads. The Vibratip costs $9. The
list price for the NC-Stat DPNCheck is the highest of
the alternative devices in our study, $1000 for the device
and another $20 per sensor, which can be used to assess
both left and right sural nerve in one patient. The TST
and NeuroQuick are not available for purchasing, and
therefore the prices are unknown. A paper published in
1989 describes that the cost of a TST was about $35
[13]. The TST and the NeuroQuick both work on two
standard type AA batteries. Durability can be increased
by using rechargeable batteries. The NC-stat DPNCheck
uses a standard 3 V Lithium Ion battery. The Neuropads
and the NC-stat DPNCheck biosensors are not suitable
for recycling; these need to be disposed after using them
for a single patient. The Vibratip can be used thousands
of times over several months [21], but eventually needs
to be disposed, as the battery is not replaceable.
Discussion and conclusions
It is important to detect leprosy neuropathy at an early
stage, as it can progress to nerve function impairment and
subsequently may lead to disabilities. In the INFIR study,
20 – 50% of the newly diagnosed leprosy patients either
had subclinical neuropathy at diagnosis or developed this
during follow up [22]. Of the patients who had subclinical
neuropathy, around 16% developed clinical NFI in the
INFIR study. Preliminary data of the TENLEP trial show
that clinical NFI developed in 8% of the subclinical patients.
Even though treatment of subclinical neuropathy has not
been successful [23, 24], knowing the subclinical status of a
patient’s nerves allows to immediately start prednisolone
treatment in the patients who do develop clinical NFI. In
this study we compared user-friendly methods for detecting
early leprosy neuropathy in field settings. We found
that the NeuroQuick and TST are promising screening
methods, especially for the sural nerve, since they show
high sensitivity and specificity and are appreciated by
both patients and assessor.
Both the NeuroQuick and the TST examine small fibre
function. It must be noted, however, that the INFIR
study found variation between the patients in the first
affected modality and type of nerve fibre – large or small
[25]. First of all, this indicates that the processes and
patterns of neuropathy are different for each individual.
Second, this has consequences for the assessment of early
neuropathy. Adding a second test method that assesses
large fibre function is recommended. Unfortunately, the
two devices in our study testing large fibres, the NC-stat
DPNCheck and the Vibratip, are not suitable for early
detection of leprosy neuropathy. So far, NCS testing is the
only reliable option to detect early large fibre neuropathy.
None of the alternative devices included in our study
was new. The TST has been used to assess sensitivity of
leprosy skin lesions [12]; the Neuropad, NeuroQuick,
Vibratip and NC-stat DPNCheck have been used for diag-
nosis of diabetes neuropathy. Studies in diabetes patients
showed generally good sensitivity and specificity for the
detection of neuropathy [19, 26–31]. Although both small
and large fibres are involved in diabetes neuropathy and in
leprosy neuropathy, diabetes neuropathy is often symmet-
rical [32] and the order of affected modalities is somewhat
different between the two diseases. In diabetes for
example, cold perception proved the most sensitive
thermal test [33], whereas in leprosy warm detection
was more sensitive [34]. Furthermore, the tests in diabetes
patients have been performed in a completely different
setting and environment, namely western hospital settings.
Therefore, it was necessary to test the devices in a leprosy
endemic country with a subtropical climate, in a field set-
ting with high temperatures and humidity. Interestingly,
the TST, designed for testing in high environmental tem-
peratures, showed good results. The temperature of the
warm-end of the TST adapts to the ambient temperature,
when between 15 °C and 45 °C. A graph with the correl-
ation is depicted on the device.
The accuracy of the reference standard test, to which
the new tests are compared, is an important point to
consider. When the reference standard test is not 100%
accurate, this has an effect on the sensitivity and specifi-
city estimates [35]. NCS test results have been compared
with nerve biopsies and were found to be accurate [36].
In addition, NCS testing is more reliable because it does
not require a response from the subject and therefore
objective. The WDT test, on the other hand, has never
been compared with a gold standard in leprosy neuropathy.
Furthermore, it requires a response from the subject and is
therefore less objective. Perkins et al. describe that variances
of 50% and higher can occur in thermal thresholds testing.
However, since we use very high cut-off levels for normality
(97.5%), we are confident that the sural nerves tested
abnormal in our study are indeed abnormal. This is less
the case for the WDT of the posterior tibial though.
We could not rely on the upper thresholds for the posterior
tibial nerve, since they mainly lay outside the measurement
range of the TSA (50 °C). Therefore, we used a lower cut-
off by taking the 95th percentile, but even with that method
it was very difficult to include abnormal nerves.
Since in leprosy sensory function generally is affected
before motor function, we did not include any assessments
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for motor nerves. Several other tests might be worthwhile
to look at in future studies. We intended to include the
NerveCheck (PhiMed Europe), which is a portable device
that assesses four modalities: cold, warm, pain and vibration
sensation [37]. Unfortunately, at the time of our study no
NerveCheck device was available for field testing. Sec-
ond, it might be interesting to look at skin wrinkling as
an autonomic function test. Although this test takes
long – 30 min – the results are quite promising in diabetes
neuropathy [38, 39].
In conclusion, based on our results the Neuropad,
NCstat DPNCheck and Vibratip do not qualify for fur-
ther testing for detection of early leprosy neuropathy.
For both the NeuroQuick and TST, however, we recom-
mend to further study three different aspects. First, the
options for further development and production on a
larger scale should be examined. Second, repeatability
and reproducibility should be determined for these two
tests, and preferably assessed in different populations as
well. Third, additional testing of the accuracy on the hands
can give more information on the usability of the two tests
in detecting early leprosy neuropathy in field settings, as
upper extremity neuropathy is common as well.
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